Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trametinib · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Trametinib experimental arm | EXPERIMENTAL | the experimental arm will be Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each. |
| Vinblastine control arm | ACTIVE_COMPARATOR | the control arm will be the weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each |
| Name | Type | Description |
|---|---|---|
| Trametinib | DRUG | Mekinist© (Trametinib) taken orally each day with a 18-course schedule of 4 weeks each. |
| Vinblastine | DRUG | weekly intra-venous Vinblastine (Velbe©) during 18 courses of 4 weeks each |
Inclusion Criteria: * Age: ≥ 1 month to ≤ 25 years * Signed written informed consent prior to study participation of the legal representatives and the patient if the patient can understand the impact of clinical trial and to give consent. For patients above 18 years, their written informed consent ...